Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

Journal of Nuclear Medicine

Volumn 52, Issue 1, 2011, Pages 81-89

  Jadvar, Hossein ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acetate; Choline; FDG; Genitourinary; Molecular imaging; PET; PET CT; Prostate

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GLUCOSE TRANSPORTER 1; PROSTATE SPECIFIC ANTIGEN;

CASTRATION; CELL STRAIN LNCAP; DISEASE SURVEILLANCE; GENE EXPRESSION; METASTASIS; NONHUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT DISEASE; REVIEW;

ACETATES; AGED; CARBON RADIOISOTOPES; CHOLINE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 79851481116     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.077941     Document Type: Review

References (80)

1. SEER Stat Fact Sheets: Prostate. Available at: http://seer.cancer.gov/ statfacts/html/prost.html. Accessed November 19, 2010.
2. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am. 2003;30:219-226. (Pubitemid 36520596)
3. Dong JT, Rinker-Schaeffer CW, Ichikawa T, et al. Prostate cancer: biology of metastasis and its clinical implications. World J Urol. 1996;14:182-189. (Pubitemid 126775160)
4. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597. (Pubitemid 29211767)
5. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol. 1999;26:407-421. (Pubitemid 29411449)
6. Jadvar H, Alavi A. Role of imaging in prostate cancer. PET Clin. 2009;4:135-138.
7. Patel AR, Jones JS, Rabets J, et al. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology. 2004;63:87-89. (Pubitemid 38147556)
8. Mazzucchelli R, Scarpelli M, Cheng L, et al. Pathology of prostate cancer and focal therapy ('male lumpectomy'). Anticancer Res. 2009;29:5155-5161.
9. Engelbrecht MR, Barentsz JO, Jager GJ, et al. Prostate cancer staging with imaging. BJU Int. 2000;86(suppl 1):123-134.
10. Macheda ML, Rogers S, Bets JD. Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-662. (Pubitemid 40175840)
11. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57:170-178. (Pubitemid 30417071)
12. Effert P, Beniers AJ, Tamimi Y, et al. Expression of glucose transporter 1 (GLUT-1) in cell lines and clinical specimen from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057-3063. (Pubitemid 39407186)
13. Stewart GD, Gray K, Pennington CJ, et al. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter 1 expression correlate with Gleason score. Oncol Rep. 2008;20:1561-1567.
14. Jadvar H, Li X, Shahinian A, et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005;4:91-97. (Pubitemid 43143795)
15. Jadvar H, Ye W, Groshen S, et al. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med. 2008;22:787-793.
16. Hillner BE, Siegel BA Shields AF, et al. relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET registry. J Nucl Med. 2008;49:1928-1935.
17. Salminen E, Hogg A, Binns D, et al. Investigations with FDG PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol. 2002;41:425-429. (Pubitemid 35222040)
18. Liu IJ, Zafar MB, Lai YH, et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108-111. (Pubitemid 32065829)
19. Kao PF, Chou YH, Lai CW. Diffuse FDG uptake in acute prostatitis. Clin Nucl Med. 2008;33:308-310.
20. 18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29:623-629.
21. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial findings of PET with FDG. Radiology. 1996;199:751-756.
22. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913-918. (Pubitemid 34522186)
23. Jadvar H, Pinski J, Quinn D, et al. PET/CT with FDG in metastatic prostate cancer: castrate-sensitive vs. castrate-resistant disease [abstract]. J Nucl Med. 2009;50(suppl):120P.
24. Chang CH, Wu HC, Tsai JJ, et al. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int. 2003;70:311-315. (Pubitemid 36566263)
25. 18F]fluoro-2- deoxyglucose positron emission tomography for detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11:4761-4769.
26. Sung J, Espiritu JI, Segall GM, et al. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int. 2003;92:24-27. (Pubitemid 36843022)
27. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322-1328. (Pubitemid 29428572)
28. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22:963-969. (Pubitemid 32783446)
29. Haberkorn U, Bellemann ME, Altmann A, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med. 1997;38:1215-1221. (Pubitemid 27332617)
30. 18F- fluorodeoxyglucose PET. Nat Rev Urol. 2009;6:317-323.
31. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11:3210-3216. (Pubitemid 40627867)
32. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 2002;4:99-104. (Pubitemid 34272714)
33. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001;28:117-122. (Pubitemid 32276075)
34. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230-234. (Pubitemid 44317255)
35. 11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008;49:327-334.
36. Pflug BR, Pecher SM, Brink AW, et al. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate. 2003;57:245-254. (Pubitemid 37267807)
37. 11C-acetate whole-body PET. J Nucl Med. 2004;45:1233-1236.
38. 11C] acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1492-1495.
39. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-186. (Pubitemid 34151040)
40. Kotzerke J, Volkmer BG, Neumaier B, et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380-1384. (Pubitemid 44392221)
41. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549-555. (Pubitemid 39663421)
42. Sandblom G, Sorensen J, Lundin N, et al. Positron emission tomography with 11C-acetate for tumor detection and localization in patients with prostate specific antigen relapse after radical prostatectomy. Urology. 2006;67:996-1000. (Pubitemid 43956436)
43. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607-611.
44. 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging. 2004;31:797.
45. 11C-acetate. J Nucl Med. 2007;48:420-428.
46. 11C]acetate in normal physiology. Eur J Nucl Med Mol Imaging. 2009;36:1453-1459.
47. Jadvar H, Gurbuz A, Li X, et al. Choline autoradiography of human prostate cancer xenograft: effect of castration. Mol Imaging. 2008;7:147-152.
48. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415-1419.
49. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:38-38.
50. 11C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumor stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1740-1741.
51. Reske SN, Blumstein NM, Glatting G. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35:9-17. (Pubitemid 350234137)
52. 18F]FDG in cultured prostate cancer cells. Nucl Med Biol. 2006;33:977-984.
53. 11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005;32:668-673.
54. 11C]choline for multi dose utilization. Appl Radiat Isot. 2004;60:835-838.
55. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110-117. (Pubitemid 32095708)
56. 11C-choline PET-CT. Radiology. 2007;244:797-806.
57. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742-748.
58. Park H, Piert MR, Khan A, et al. Registration methodology for histological sections and in vivo imaging of human prostate. Acad Radiol. 2008;15:1027-1039. (Pubitemid 351953912)
59. Eschmann SM, Pfannenberg AC, Rieger A, et al. Comparison of 11C-choline PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007;46:161-168. (Pubitemid 47612279)
60. Rinnab L, Blumstein NM, Mottaghy FM, et al. 11C-choline positron emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int. 2007;99:1421-1426. (Pubitemid 47164799)
61. 11C-choline PET and PET-CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:45-53.
62. 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642-1649.
63. Martorana G, Schiavina R, Cort B, et al. 11C-choline positron emission tomography/computed tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 2006;176:954-960. (Pubitemid 44142558)
64. Picchio M, Crivellaro C, Giovacchini G, et al. PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging. 2009;53:245-268.
65. 11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
66. 11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Radiol. 2007;52:423-429.
67. 11C]choline positron emission tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786-793.
68. 11C-choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumor stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065-1073.
69. 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394-1400.
70. 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol. 2010;12:210-217.
71. 11C] acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin. 2003;42:25-30.
72. Price DT, Coleman RE, Liao RP, et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273-280. (Pubitemid 34640843)
73. 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localization of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:976-983.
74. Kwee SA, Coel MN, Lim J, et al. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173:252-255. (Pubitemid 39627729)
75. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925-933.
76. Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009;11:446-454.
77. 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766-1774.
78. 18F)-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113:895-904.
79. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18 fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/mL? Mol Imaging Biol. 2006;8:43-48.
80. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031-2041.